Jeff Bird

Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ.

Tecan Genomics, Inc. provides genomics sample preparation solutions. It offers solutions which make biological samples accessible for genomic analysis. The firm has commercialized numerous proprietary DNA and RNA sample preparation products for use in research and diagnostic applications. The company was founded by Jan D'Alvise, James W. Larrick and Nurith Kurn in 2000 and is headquartered in San Carlos, CA.

TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA.

Stanford Health Care provides healthcare services. It services includes cardiac care, cancer treatment, neurosciences, surgery and organ transplants. The company was founded in 1956 and is headquartered in Stanford, CA.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Procyrion, Inc. manufactures medical devices. The firm develops percutaneous circulatory assist device intended to treat chronic heart failure. Its product Aortix is a catheter deployed circulatory assist device for the millions of heart failure patients who are too sick for medication alone. The company was founded by Reynolds M. Delgado III in 2005 and is headquartered in Houston, TX.

Theracos, Inc. operates as a pharmaceutical research and development company. The firm supports preclinical & clinical research & development in inflammatory, metabolic and affective disorders. It specializes in all aspects of pharmaceutical development including medicinal and process chemistry, pharmacology, toxicology, pharmacokinetics, manufacturing, formulation, QA/QC, regulatory affairs and the design and execution of clinical trials. The company was founded by Edward P. Amento and is headquartered in Marlborough, MA.

Helix OpCo LLC is a genomics company. It offers consumer genetics, next generation sequencing (ngs), bioinformatics, consumer insights, big data, dna, population health, and genomics. The company was founded by Justin Kao, Scott Burke, Jay T Flatley and James Lu in 2015 and is headquartered in San Mateo, CA.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Procyrion, Inc. manufactures medical devices. The firm develops percutaneous circulatory assist device intended to treat chronic heart failure. Its product Aortix is a catheter deployed circulatory assist device for the millions of heart failure patients who are too sick for medication alone. The company was founded by Reynolds M. Delgado III in 2005 and is headquartered in Houston, TX.

Helix OpCo LLC is a genomics company. It offers consumer genetics, next generation sequencing (ngs), bioinformatics, consumer insights, big data, dna, population health, and genomics. The company was founded by Justin Kao, Scott Burke, Jay T Flatley and James Lu in 2015 and is headquartered in San Mateo, CA.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Helix OpCo LLC is a genomics company. It offers consumer genetics, next generation sequencing (ngs), bioinformatics, consumer insights, big data, dna, population health, and genomics. The company was founded by Justin Kao, Scott Burke, Jay T Flatley and James Lu in 2015 and is headquartered in San Mateo, CA.

Sutter Hill Ventures LLC (Sutter Hill Ventures) is a venture capital firm founded in 1962 by Paul M Wythes and Bill H Draper. The firm is headquartered in Palo Alto, California.

Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ.

Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA.

Sutter Hill Ventures LLC (Sutter Hill Ventures) is a venture capital firm founded in 1962 by Paul M Wythes and Bill H Draper. The firm is headquartered in Palo Alto, California.

TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA.

Sutter Hill Ventures LLC (Sutter Hill Ventures) is a venture capital firm founded in 1962 by Paul M Wythes and Bill H Draper. The firm is headquartered in Palo Alto, California.

Theracos, Inc. operates as a pharmaceutical research and development company. The firm supports preclinical & clinical research & development in inflammatory, metabolic and affective disorders. It specializes in all aspects of pharmaceutical development including medicinal and process chemistry, pharmacology, toxicology, pharmacokinetics, manufacturing, formulation, QA/QC, regulatory affairs and the design and execution of clinical trials. The company was founded by Edward P. Amento and is headquartered in Marlborough, MA.

Procyrion, Inc. manufactures medical devices. The firm develops percutaneous circulatory assist device intended to treat chronic heart failure. Its product Aortix is a catheter deployed circulatory assist device for the millions of heart failure patients who are too sick for medication alone. The company was founded by Reynolds M. Delgado III in 2005 and is headquartered in Houston, TX.

Procyrion, Inc. manufactures medical devices. The firm develops percutaneous circulatory assist device intended to treat chronic heart failure. Its product Aortix is a catheter deployed circulatory assist device for the millions of heart failure patients who are too sick for medication alone. The company was founded by Reynolds M. Delgado III in 2005 and is headquartered in Houston, TX.

Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA.

Procyrion, Inc. manufactures medical devices. The firm develops percutaneous circulatory assist device intended to treat chronic heart failure. Its product Aortix is a catheter deployed circulatory assist device for the millions of heart failure patients who are too sick for medication alone. The company was founded by Reynolds M. Delgado III in 2005 and is headquartered in Houston, TX.

Theracos, Inc. operates as a pharmaceutical research and development company. The firm supports preclinical & clinical research & development in inflammatory, metabolic and affective disorders. It specializes in all aspects of pharmaceutical development including medicinal and process chemistry, pharmacology, toxicology, pharmacokinetics, manufacturing, formulation, QA/QC, regulatory affairs and the design and execution of clinical trials. The company was founded by Edward P. Amento and is headquartered in Marlborough, MA.

Theracos, Inc. operates as a pharmaceutical research and development company. The firm supports preclinical & clinical research & development in inflammatory, metabolic and affective disorders. It specializes in all aspects of pharmaceutical development including medicinal and process chemistry, pharmacology, toxicology, pharmacokinetics, manufacturing, formulation, QA/QC, regulatory affairs and the design and execution of clinical trials. The company was founded by Edward P. Amento and is headquartered in Marlborough, MA.

Sutter Hill Ventures LLC (Sutter Hill Ventures) is a venture capital firm founded in 1962 by Paul M Wythes and Bill H Draper. The firm is headquartered in Palo Alto, California.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ.

Procyrion, Inc. manufactures medical devices. The firm develops percutaneous circulatory assist device intended to treat chronic heart failure. Its product Aortix is a catheter deployed circulatory assist device for the millions of heart failure patients who are too sick for medication alone. The company was founded by Reynolds M. Delgado III in 2005 and is headquartered in Houston, TX.

Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA.

Sutter Hill Ventures LLC (Sutter Hill Ventures) is a venture capital firm founded in 1962 by Paul M Wythes and Bill H Draper. The firm is headquartered in Palo Alto, California.